Feed NLSP
NL

NLS Pharmaceutics AG

NLSP · NASDAQ

$3.15 -4.83% (-$0.16)
Piotroski F-Score Weak
2/9
Valuation
-
N/A
P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
-
N/A
ROIC N/A
ROE N/A
ROA N/A
Debt
-
N/A
Debt/Equity N/A
Current ratio N/A
Int. coverage N/A
Stability
0 /100
Unstable
Beta 0.13x
Rev. volatility N/A
EPS volatility N/A

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o NLSP
Online

O podjetju

NLS Pharmaceutics AG (NLS) is a Swiss biotechnology company focused on the development of innovative drugs for the treatment of neurological and psychiatric disorders. With a primary focus on researching and developing medications for epilepsy and mood disorders, NLS Pharmaceutics aims to address unmet needs in the treatment of these diseases. The company is known for its expertise in pharmacology and neuroscience and for its commitment to innovation and discovering new therapeutic approaches. Shares of NLS Pharmaceutics AG (NLS) could be suitable for investors looking to invest in the biotechnology sector with an emphasis on treating neurological and psychiatric disorders.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Alexander Zwyer

Employees

6

Headquarters

Zurich

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.